Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats

被引:11
作者
Hauptmann, J
Steinmetzer, T
Vieweg, H
Wikström, P
Stürzebecher, J
机构
[1] Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany
[2] Univ Jena, Dept Biochem & Biophys, D-07743 Jena, Germany
[3] Pentapharm Ltd, CH-4002 Basel, Switzerland
关键词
thrombin inhibitors; structures; charged groups; systemic clearance; biliary clearance;
D O I
10.1023/A:1016426724831
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Systemic and hepato-biliary clearance of peptidomimetic thrombin inhibitors of the 4-amidinophenylalanine amide-type, derived from NAPAP (Nalpha-[2-naphthylsulfonyl-glycyl]-4-amidinophenylalanine-piperidide) by substituting Gly in P2 for natural and unnatural amino acids or by varying the C- and N-terminal moieties, resp., were investigated. Methods. Concentrations of the compounds administered as intravenous bolus injection at a dose of 1 mg/kg to bile duct-cannulated rats were determined in plasma and bile samples collected over 4 hours using reversed-phase HPLC. Results. NAPAP and the derivatives with additional charged groups are comparatively hydrophilic compounds. For NAPAP and most of the derivatives the biliary clearance accounted for a high percentage of the rapid systemic plasma clearance. Derivatives 2a-c with a second basic group in P2 position showed lower systemic and biliary clearance compared to NAPAP, whereas their cumulative biliary excretion after a period of 120 min was less affected. Bis-benzamidine derivatives 4a and 5 with the second amidino group in the N-terminal moiety had the lowest biliary clearance. Additional carboxylic groups reduced the systemic and biliary clearance only as free amidinophenylalanine carboxyl in 3a and 5. No influence compared to NAPAP was observed for 2d with a free carboxyl group in P2 position. Conclusions. The weak correlation of the log P values of the compounds with the clearance parameters indicates the influence of structural variations, especially of charged groups, in this series of compounds rather than overall lipophilicity on hepato-biliary elimination mediated by hepatocellular transporters.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 31 条
[1]  
Ahmad S, 2000, INT ANGIOL, V19, P126
[2]   Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat [J].
Blakey, GE ;
Nestorov, IA ;
Arundel, PA ;
Aarons, LJ ;
Rowland, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (03) :277-312
[3]   ARGATROBAN, A SELECTIVE, POTENT THROMBIN INHIBITOR [J].
BUSH, LR .
CARDIOVASCULAR DRUG REVIEWS, 1991, 9 (03) :247-263
[4]   PHARMACOLOGICAL CHARACTERIZATION OF A NEW 4-AMIDINOPHENYL-ALANINE THROMBIN-INHIBITOR (CRC-220) [J].
DICKNEITE, G ;
SEIFFGE, D ;
DIEHL, KH ;
REERS, M ;
CZECH, J ;
WEINMANN, E ;
HOFFMANN, D ;
STUBER, T .
THROMBOSIS RESEARCH, 1995, 77 (04) :357-368
[5]   First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver - Introduction with bile acid transport systems [J].
Eckhardt, U ;
Stuber, W ;
Dickneite, G ;
Reers, M ;
Petzinger, E .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (01) :85-96
[6]  
Eriksson UG, 1998, BIOPHARM DRUG DISPOS, V19, P55, DOI 10.1002/(SICI)1099-081X(199801)19:1<55::AID-BDD74>3.0.CO
[7]  
2-H
[8]   Design of benzamidine-type inhibitors of factor Xa [J].
Gabriel, B ;
Stubbs, MT ;
Bergner, A ;
Hauptmann, J ;
Bode, W ;
Stürzebecher, J ;
Moroder, L .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (22) :4240-4250
[9]   Synthetic inhibitors of thrombin and factor Xa:: From bench to bedside [J].
Hauptmann, J ;
Stürzebecher, J .
THROMBOSIS RESEARCH, 1999, 93 (05) :203-241
[10]  
HAUPTMANN J, 1987, BIOMED BIOCHIM ACTA, V46, P445